MYOCARDITIS AND RHABDOMYOLYSIS INCIDENCE WITH IMMUNE CHECKPOINT INHIBITORS
| Autor: | Douglas B. Johnson, Matthew R Alexander, Daniel J. Lenihan, Javid Moslehi, David Slosky, Tyler Bloomer, Jeffrey A. Sosman, Jason R Becker |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Myocarditis
biology business.industry Cancer chemical and pharmacologic phenomena Ipilimumab medicine.disease Virology 03 medical and health sciences 0302 clinical medicine Immune system Antigen 030220 oncology & carcinogenesis Immunology medicine biology.protein Antibody Nivolumab Cardiology and Cardiovascular Medicine business Rhabdomyolysis 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of the American College of Cardiology. 69:943 |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/s0735-1097(17)34332-2 |
| Popis: | Background: Immune checkpoint inhibitors have expanded treatment options for a number of cancer types by enhancing anti-tumor immune responses. Specifically, ipilimumab, an anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) antibody, and nivolumab, an anti-programmed death 1 (PD-1) antibody |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|